🚀 VC round data is live in beta, check it out!
Climb Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Climb Bio and similar public comparables like Recbio, Monopar Therapeutics, Formycon, Akebia Therapeutics and more.
Climb Bio Overview
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Founded
2018
HQ
Employees
18
Website
Sectors
Financials (LTM)
EV
$284M
Climb Bio Financials
Climb Bio reported last 12-month revenue of — and negative EBITDA of ($71M).
In the same LTM period, Climb Bio generated — in gross profit, ($71M) in EBITDA losses, and had net loss of ($64M).
Revenue (LTM)
Climb Bio P&L
In the most recent fiscal year, Climb Bio reported revenue of — and EBITDA of ($68M).
Climb Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($71M) | XXX | ($68M) | XXX | XXX | XXX |
| Net Profit | ($64M) | XXX | ($60M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Climb Bio Stock Performance
Climb Bio has current market cap of $384M, and enterprise value of $284M.
Market Cap Evolution
Climb Bio's stock price is $8.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $284M | $384M | 13.3% | XXX | XXX | XXX | $-1.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialClimb Bio Valuation Multiples
Climb Bio trades at (4.0x) EV/EBITDA.
Climb Bio Financial Valuation Multiples
As of April 10, 2026, Climb Bio has market cap of $384M and EV of $284M.
Equity research analysts estimate Climb Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Climb Bio has a P/E ratio of (6.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $384M | XXX | $384M | XXX | XXX | XXX |
| EV (current) | $284M | XXX | $284M | XXX | XXX | XXX |
| EV/EBITDA | (4.0x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/EBIT | (4.0x) | XXX | (4.2x) | XXX | XXX | XXX |
| P/E | (6.0x) | XXX | (6.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Climb Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Climb Bio Margins & Growth Rates
Climb Bio's revenue in the last fiscal year grew by —.
Climb Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.8M for the same period.
Climb Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 19% | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Climb Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Monopar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Formycon | XXX | XXX | XXX | XXX | XXX | XXX |
| Akebia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Benitec Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Climb Bio M&A Activity
Climb Bio acquired XXX companies to date.
Last acquisition by Climb Bio was on XXXXXXXX, XXXXX. Climb Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Climb Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialClimb Bio Investment Activity
Climb Bio invested in XXX companies to date.
Climb Bio made its latest investment on XXXXXXXX, XXXXX. Climb Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Climb Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Climb Bio
| When was Climb Bio founded? | Climb Bio was founded in 2018. |
| Where is Climb Bio headquartered? | Climb Bio is headquartered in United States. |
| How many employees does Climb Bio have? | As of today, Climb Bio has over 18 employees. |
| Who is the CEO of Climb Bio? | Climb Bio's CEO is Aoife M. Brennan. |
| Is Climb Bio publicly listed? | Yes, Climb Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Climb Bio? | Climb Bio trades under CLYM ticker. |
| When did Climb Bio go public? | Climb Bio went public in 2021. |
| Who are competitors of Climb Bio? | Climb Bio main competitors are Recbio, Monopar Therapeutics, Formycon, Akebia Therapeutics. |
| What is the current market cap of Climb Bio? | Climb Bio's current market cap is $384M. |
| Is Climb Bio profitable? | No, Climb Bio is not profitable. |
| What is the current EBITDA of Climb Bio? | Climb Bio has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Climb Bio? | Current EBITDA multiple of Climb Bio is (4.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.